Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

VLX60 characterization II

ABSTRACT: Microarray based mRNA profiling was used to identify the mechanism of action for the small molecule VLX60.

ORGANISM(S): Homo sapiens

PROVIDER: GSE86309 | GEO | 2017/07/04

SECONDARY ACCESSION(S): PRJNA341386

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

VLX60 characterization

Project description:Microarray based mRNA profiling was used to identify the mechanism of action for the small molecule VLX60.

2015-05-28 | GSE58526 | GEO

VLX600 characterization

Project description:Microarray based mRNA profiling was used to identify the mechanism of action for the small molecule VLX600.

2016-12-07 | GSE84051 | GEO

VLX60 characterization

Project description:Microarray based mRNA profiling was used to identify the mechanism of action for the small molecule VLX60. MCF7 cells were treated with the drug candidate VLX60 for 6h prior to RNA isolation

2015-05-28 | E-GEOD-58526 | biostudies-arrayexpress

b-AP15, a novel proteasome inhibitor

Project description:Microarray based mRNA profiling was used to identify the mechanism of action for the small molecule b-AP15.

2011-10-17 | GSE24150 | GEO

PCPTC screening

2011-09-09 | GSE24027 | GEO

b-AP15, a novel proteasome inhibitor

Project description:Microarray based mRNA profiling was used to identify the mechanism of action for the small molecule b-AP15. MCF7 cells were treated with b-AP15 (1µM) or vehicle for 6 hours, followed by RNA isolation and gene expression analysis.

2011-10-16 | E-GEOD-24150 | biostudies-arrayexpress

PCPTC screening

Project description:Primary cultures of patient tumor cells (PCPTC) were used in a cell-based cytotoxicity screen. Microarray-based mRNA profiling was used to identify the mechanism-of-action for the small molecule VLX 50. MCF7 cells were treated with the PCPTC screening hit VLX 50 or DMSO control for 6h prior to RNA isolation. One sample per treatment. Data were analyzed using both MAS5.0 and RMA.

2011-09-08 | E-GEOD-24027 | biostudies-arrayexpress

The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia

Project description:SPC2996 is a novel locked nucleic acid (LNA) phosphorothioate antisense molecule targeting the mRNA of the Bcl-2 oncoprotein. We investigated the mechanism of action of SPC2996 and the basis for its clinically observed immunostimulatory effects in chronic lymphocytic leukemia (CLL). Patients with relapsed CLL were treated with a maximum of six doses of SPC2996 (0.2-6mg/ kg) in a multicenter phase I trial. Microarray-based transcriptional profiling of circulating CLL cells was carried out before and after the first infusion of SPC2996 in eighteen patients. We used microarrays to characterize global gene expression changes of circulating CLL cells in response to SPC2996 infusion in 18 patients Key word : Response to therapeutic agent We performed microarray-based gene expression profiling in serial peripheral blood samples from 18 individual CLL patients before and after treatment with SPC2996

2011-05-30 | E-GEOD-27858 | biostudies-arrayexpress

Spheroid model system (II)

Project description:Microarray based mRNA profiling was used to charactarize and compare the gene expression in cells grown as monolayer or spheroids. Keywords: Expression profiling by array

2014-02-17 | GSE53631 | GEO

HC2091 kills Mycobacterium tuberculosis by targeting the MmpL3 mycolic acid transporter

Project description:The purpose of this study was to characterize the mechanism of action of the small molecule HC2091

2018-04-09 | GSE107485 | GEO